Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Kobayashi Pharma Scraps Medium-Term Biz Plan Due to Beni-Koji Scandal
February 12, 2025
- Cheplapharm Set to Expand LLP Deals to 20 APIs, Sees Opportunities Despite Headwinds
February 12, 2025
- Eisai/Lion to Discontinue Antiplatelet Bufferin in Japan
February 12, 2025
- Sanofi Japan Files Dupixent for Asthma in Children Aged 6-11
February 12, 2025
- Kyowa Kirin Sees Need for Shift of Japan Business: CEO
February 10, 2025
- Japan Ethical Drug Sales Surge 7.3% in December: Crecon
February 10, 2025
- Kisunla Virtually Has No Impact on Leqembi Sales: Eisai
February 10, 2025
- Bain Picks Up Mitsubishi Tanabe for Over 500 Billion Yen
February 10, 2025
- Meiji to Jointly Market Taisho’s Insomnia Med Vornorexant
February 10, 2025
- Bain Strikes Deal to Buy Mitsubishi Tanabe
February 7, 2025
- UCB Bags Japan Approval for Bimzelx’s 320 mg Auto-Injector
February 7, 2025
- AstraZeneca Looks to Keep No.1 Spot in Japan Oncology Space, Driven by Bispecific Antibodies
February 7, 2025
- Kura/Kyowa Kirin’s AML Drug Inches Closer to FDA Filing on Positive PII Data
February 7, 2025
- Kyowa Kirin’s Profit Sags on R&D Spending, but Overseas Biz Fares Well
February 7, 2025
- Keytruda Extends Top Title Winning Streak to 16th Month in January: Encise
February 7, 2025
- Celltrion Set for 6 Biosimilar Filings in 2 Years, Sees Japanese Data Waiver as a Boon
February 6, 2025
- Izervay Filed for Conditional Approval in Japan: Astellas
February 6, 2025
- FRONTEO/Shionogi Eye FY2026 Approval for AI-Powered Cognitive Test
February 6, 2025
- Sumitomo Pharma CEO Hails Appointment of Parent Firm’s New President
February 5, 2025
- Astellas to Revamp Management in April, Consolidate R&D Functions
February 5, 2025
ページ
Japan is opening a new chapter in sleep medicine. The recent decision to allow medical institutions to advertise “sleep disorders”…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…